An antibody that boosts muscle mass could mean independence for the frail and elderly. Learn how Novartis research aims to improve healthy aging.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.

Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.

Jean Silveri shares key insights from her legal career.

Ahead of World Malaria Day, Novartis and Malaria No More delivered 2 million pediatric antimalarials to Zambia provided through the Power of One campaign.

Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Researchers race to put hydroxychloroquine to the test in a large study.